Tirzepatide weight loss per week: what the evidence actually shows

How weekly weight loss actually unfolds on tirzepatide, and why the average hides a lot

The 72-week average from SURMOUNT-1 tells you where people ended up, not how they got there. In practice, the first few weeks on the 2.5 mg starter dose are largely about giving your body time to adjust, the lower dose is there to reduce nausea, not to drive weight loss at speed. Most of the meaningful reduction happens as the dose increases over months. Early weeks may see very little change on the scales; later weeks, particularly after hitting a higher maintenance dose, often see faster progress. That's a normal pattern, not a sign that treatment isn't working.

Individual variation is genuinely large. Body weight, metabolic rate, starting diet, activity level, adherence to a reduced-calorie approach, all of these shift the outcome. Some people lose considerably faster than the trial average; others more slowly. The SURMOUNT-1 data covers participants who lost anywhere from a small amount to more than 25% of starting weight. If you're curious about how much weight loss to expect in week 1 of Mounjaro, our dedicated page sets out what the evidence actually shows for that opening period. And if you want a clearer picture of how much weight loss a week on Mounjaro looks like across the full course of treatment, that page breaks down the weekly pattern in plain terms. If you want to understand what the dose schedule looks like week by week, our page on how much tirzepatide is given per week walks through the licensed titration in plain terms.

The key practical point: results accumulate over months, not days. Expecting rapid dramatic loss in week one is the fastest route to disappointment with a medicine that is genuinely effective over a sustained period.

What drives the cost of tirzepatide in the UK, and what 'cheaper' often really means

UK private pricing for tirzepatide changed significantly from 1 September 2025, when Eli Lilly raised its list price substantially. Widely reported figures put the highest dose's list price rising to around £330 per four-week pen; typical private market prices since then have ranged roughly £149–£375 per month depending on dose and provider. Those numbers matter because they set the context for any price you see advertised.

A headline monthly price does not always include everything the treatment actually requires. Consultation fees, prescription fees, delivery charges, and clinical aftercare are sometimes itemised separately, meaning the number in the advert is the floor, not the ceiling. For detail on how UK tirzepatide pricing breaks down across the market, our tirzepatide weight-loss price page covers the full picture. And for a broader comparison of what different services include, tirzepatide for weight-loss cost is worth reading before you commit anywhere.

Delivery, aftercare, and the clinical review before every repeat order are the components most likely to be missing from a cheap listing, not immediately visible until something goes wrong or a dose review is needed.

Where nume sits on price, and why that's a deliberate choice

We're not the cheapest option. That's a decision, not an oversight. One transparent price covers everything: the consultation, the prescription, the treatment, next-working-day tracked delivery by DPD in plain packaging, and seven-day-a-week priority aftercare. There are no subscription fees, no auto-renewals, and every repeat order is clinically reviewed before it ships. You can see current treatment pricing on our weight-loss treatments page.

We run no discount codes, vouchers, or promotional offers on prescription medicines. That's not an oversight either, POMs aren't an appropriate category for price promotions, and any seller offering a discount code on tirzepatide is worth treating with caution. The MHRA's Yellow Card service allows you to report suspect sellers of weight-loss medicines, and that route exists because counterfeit pens are a real, documented problem in the UK market.

Our prescribers are GPhC-registered Independent Prescribers. Every consultation is personally reviewed (the same day) by a named clinician. You can verify our pharmacy on the GPhC register at any time; our registration number is 9012878. There's a lot of comfort in knowing the pen now sitting in your fridge door is from a supply chain you've actually verified.

Why 'cheapest' is the wrong test for a prescription medicine

A small monthly saving is not the metric that keeps you safe on a prescription-only medicine. Tirzepatide's supply chain matters. The MHRA has warned publicly about counterfeit weight-loss pens sold via social media and unverified websites; seizures of fake pens (some found to contain insulin rather than tirzepatide) have led to hospitalisations. The right questions to ask any provider are whether they hold a GPhC-registered pharmacy, whether a qualified prescriber reviews every order, and whether treatment is dispatched through the licensed UK supply chain.

For a prescription medicine that works over months, the quality of clinical oversight across that whole period is what determines whether treatment is safe and effective. A low entry price that comes with no aftercare, no dose-review support, or an unverifiable supply chain may not be a saving at all. Our about us page sets out how we work in full, and if you have questions before starting, our team is reachable via contact. When you're ready to check your eligibility with one of our prescribers, the right place to start is a free consultation.